U.S. Markets closed

Pluristem Therapeutics Inc. (PSTI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.390.00 (0.00%)
At close: 4:00PM EDT
People also watch
  • the Board agreed to issue Mr. Yanay a restricted stock grant of an aggregate of 2,000,000 shares . I first read his salary and said not so bad but am I reading how much stock these guys just gave themselves?
  • Next Tuesday ! Get Ready....For...Breakout...Betty ! Are..You....Ready...Teddy ?


    Future Cell Therapy Commercialization Summit
    Join the leaders and pioneers in a collaborative platform to ensure novel cell therapies are delivered to patients at scale & commercialized
  • Neupogen vs PLX R18

    In searching for study results for Neupogen, I found an incredibly interesting tidbit. In their study from 2013, they used only male NHP's

    "Study AXR01 (35) was conducted to define a rhesus macaque model of H-ARS. This
    well-characterized model of H-ARS would be used to assess the efficacy of drug
    products proposed for the treatment of H-ARS. Forty-eight male rhesus macaques
    (Macaca mulatta) were exposed to 6 MV of bilateral, TBI administered by a photon
    linear accelerator (LINAC)."


    We had 100% survival rate in males with the 2 lower doses. So what would Neupogen's survival rate have been if it included females in the study? How did they not include females? Why did Pluristem's include both and not theirs? Could you imagine the difference in our price right now if we showed 100% survival. This now becomes an unfair comparison between the two. ARRRGGHHHHH!!!

  • Check This Out ! You Can Bet Pluristem Was At This Meeting This Past Monday IMO !


    U.S. Department of Defense Officials Introduce New Strategies to Stimulate Medical Countermeasures Development
    For the past several years, BIO has had the opportunity to partner with the U.S. Department of Defense (DoD) during the annual BIO International Convention to provide an open forum to discuss the c…
  • Hey 1stock. You were showing Neupogen's ARS study had 79%/41% survival to placebo. Edison report is showing 79%/59%. Where did you get these results. I was looking around and did find some things on Neupogens trials, and some/most primates also needed blood transfusions and antibiotics. Edison's numbers give us a better rate, and would just like to find something myself. Seeing different numbers from a few different sources, so I don't know what to think.
  • GIDDY-UP ! From Edison Research Report !

    ARS would qualify for a priority review voucher.

    The legislation regarding the award of priority review vouchers (PRVs) was expanded under the 21st Century Cures Act to include products that address a threat to national security. PLX-R18 should therefore be eligible for such a voucher. The most recent sale of a PRV was for $125m (from Sarepta to Gilead in February 2017), although we expect these prices to drop with the expansion of the program.
  • Seems like they have been playing with government money for a long time.
  • PLX is PSTI? what would you pick? both Israel based and similar market caps. imo PLX with it's ProCellex platform proved already they can deliver superior cell plant ERTs by having Elelyso approved in 2012. Fabry and CF data in the current pipeline looks very good. Potential is huge just patience.
  • Food For Thought !

    It Just Occurred To Me After Re-Reading The Actions Of The Board of Directors Both In March..2-CEO's.. And Now In June... On The Surface At Least, It Appears They May Be Preparing To Split The Company Into 2 Separate Units ?

    IMO..If That Is In Fact What They Are Planning ? I Would Guess They Would Make PLX-R18 As One Stand Alone Entity & PLX-PAD As Another ?

    Sounds Wild, But It May Make Good Logistical Business Sense As Each Product Does Have Indications In Large Markets And Besides Any Company With Future Takeover Plans Would Have To Take-Over 2 Companies !

    Does Anyone Else Think This Is A Possibility ? If They Are Laying The Goundwork For Such A Move, We Long Shareholders Would Own Equal Shares In Both Companies... To That I Would Say: GIDDY-UP !
  • It's been a while since I've been around here, but I see Allo is still up to the same nonsense from 6 years ago. Funny how nothing changes on this board and nothing changes with the company. Zami & Yaky, and Allo all need to go.
  • http://www.edisoninvestmentresearch.com/research/report/pluristem-therapeutics1/preview/

    Positive trends in radiation treatment | Pluristem Therapeutics
    Pluristem reported data from its pilot study of PLX-R18 for the treatment of acute radiation syndrome (ARS). The study included 48 non-human primates (NHP) who were dosed with 4m, 10m, and 20m cells per kg and showed an improvement in survival to 83%
  • New Video.


    Cell therapy - the next generation of biological therapeutic products - Pluristem Therapeutics Inc.
  • I think bluehorses hit the mark on where a lot of people are at. At least with this: "their reputation is at stake as a company." More specificially that "they put the guidance out for 2017 and if they don't hit the marks, you can buy this stock for pennies and they should be voted out." I am not yet as critical of the dual-CEO idea or of Yaky and Zami as some of you guys are, but this year has been built up with expectations by them, and if they don't deliver, it should be them on the chopping blocks. I can understand the China deal not going through for the moment, only because there is a lot of blossoming and changes going on in that country to the point where I can see why a deal might need to be scrapped and started over from the beginning. I'm not an expert, it just seems like something that wouldn't be hard to imagine. As for the Sosei deal, I have no idea. That's already been delayed but apparently they are expecting it to be hammered out in Q3/2017? The big whopper to me will be what the United States decides to do going forward. If we can get a contract that will pay our bills for the next 3-5 years, I think this stock would move big time. Or maybe on a longer shot, if something incredible came out of Fukushima or the NY Blood Center. Still a lot to wait for this year and we should at least give the benefit of the doubt for the rest of the year, IMHO, before we break out the pitchforks. They do have 3 Phase III trials about to start, and cruising between $1.25-$1.50 seems low to me for a company with this far advanced trials, US gov't sponsorship, patented manufacturing processes, and with such good trial results in every indication they've touched so far. I don't know whats going on with the partnerships, if it is a problem with the CEOs, but we have great products with only a couple years needed for approval, IMHO. Reassessing my position and commitment to this company at the end of December. Have shares and options. Been long for 7 years at least, in case you were wondering.
  • With partners dropping out there is something going on...there either making a big deal with only one merger or the ARS product buyer wants control as a national security issue..
  • one🌱sees🌱the🌱mud🌱and🌱the🌱other🌱the🌱stars.http://dataunion.tistory.com/8868

    Pluristem Therapeutics Inc. NASDAQ $PSTI Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.3 In other words, the correlation coefficient of the other stock
  • http://www.raps.org/Regulatory-Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-You-Need-to-Know-About-FDA%E2%80%99s-Priority-Review-Vouchers/

    Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers
    Since 2007, the US Food and Drug Administration (FDA) has issued a handful of special "priority review" vouchers which allow its recipient to expedite the review of any one of its new drug products. What are these vouchers, why is FDA issuing them an
  • I think we are soon going to be in trouble if nothing significant happens soon. This year was touted by management as a breakout type of year, yet the half way mark is approaching quickly, with crickets a chirping.

    Still wonder about the Sosei deal. Are they waiting for them to have a bigger stash of cash since the Chinese deal fell through. We're they banking on extraordinary results in ARS to boost price so they can raise funds easier. I can't believe after the many years of saying partership will come, we have nothing.

    Then there's the state of the art manufacturing plant really doing little. Not only did it waste two years of progression with trials, they expanded it. Why? So it can sit idle and look good in pictures. Imagine if they were producing cells for others all this time. Imagine the cash they would have. Boggles my mind.

    Just venting as I have had luck with news being released after I vent. Really getting discouraged and can't believe there is no movement in price. Here's to hoping they pull that proverbial rabbit out of their hat.
  • Jackie (Allo) no longer is working for the public relations company she used to work. So, looks like we've heard the last of Jackie (Allo)
  • (AXSM) Mcap $90 M /Cash $55 M / 5x Phase 3 programs in various indications targeting huge Markets with first results in Q3 2017 =10+ BAGGER ... The next big player in the making here ! GLTA

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • Buteo has long been silent - if you are still reading and willing to post can you comment on why you believe investing in PSTI has been so very disappointing in spite of its great potential - a potential you believed and often assured us would carry it into stratospheric numbers??